FGFR4 and lymphangioleiomyomatosis: The presence of the TSC2 mutation in PBMCs also raises the possibility of systemic involvement, potentially acting alongside FGFR4 variants to amplify pro-fibrotic signaling or support abnormal proliferation of LAM cells.